SCHEMBL4310344

SCHEMBL4310344

Clc1cnncn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL933680 0.68
SCHEMBL11633170 0.67
SCHEMBL9795348 0.62
SCHEMBL3630395 0.62
SCHEMBL31051471 0.62
SCHEMBL2905139 0.60
SCHEMBL24201630 0.59 HCAR2 (0.38)
SCHEMBL29351819 0.57 ALDH1A1 (0.52)
SCHEMBL22245644 0.57
SCHEMBL6771 0.56

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-10265464-A None JP disclosed
US-20240315246-A1 METHOD OF USING SIMAZINE FOR CONTROLLING ANNUAL BLUEGRASS IN COOL SEASON-TURFGRASSES HOWARD HAROLD F (US) 2024-09-26 US disclosed
WO-2024197286-A1 A METHOD OF USING SIMAZINE FOR CONTROLLING ANNUAL BLUEGRASS IN COOL-SEASON TURFGRASSES HOWARD HAROLD F (US) 2024-09-26 WO disclosed
EP-1871765-B1 3-(INDAZOL-5-YL)-(1,2,4)TRIAZINE DERIVATIVES AND RELATED COMPOUNDS AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER SCHERING CORP (US) 2009-12-09 EP disclosed
US-7528132-B2 immunodeficiencies, cancers, cardiovascular diseases, endocrine disorders, Parkinson's disease, metabolic diseases, tumorigenesis, Alzheimer's disease, heart disease, diabetes, neurodegeneration, inflammation, kidney disease, atherosclerosis and airway disease; indazolyl [1,2,4]triazine compounds SCHERING CORPORATION (US) 2009-05-05 US disclosed
US-20080004257-A1 Kinase inhibitors SCHERING CORPORATION 2008-01-03 US disclosed
EP-1871765-A2 3-(INDAZOL-5-YL)-(1,2,4)TRIAZINE DERIVATIVES AND RELATED COMPOUNDS AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER SCHERING CORPORATION (US) 2008-01-02 EP disclosed
WO-2006081230-A2 3-(INDAZOL-5-YL)-(1,2, 4) TRIAZINE DERIVATIVES AND RELATED COMPOUNDS AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER SCHERING CORPORATION (US) 2006-08-03 WO disclosed
US-6159974-A LDL receptor gene expression promoters SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2000-12-12 US disclosed
JP-H10265464-A EXPRESSION ENHANCER OF LDL RECEPTOR GENE SUMITOMO PHARMACEUT CO LTD 1998-10-06 JP disclosed